Cargando…

Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia

BACKGROUND: Pentavalent antimonials have been the first line treatment for dermal leishmaniasis in Colombia for over 30 years. Miltefosine is administered as second line treatment since 2005. The susceptibility of circulating populations of Leishmania to these drugs is unknown despite clinical evide...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández, Olga Lucía, Diaz-Toro, Yira, Ovalle, Clemencia, Valderrama, Liliana, Muvdi, Sandra, Rodríguez, Isabel, Gomez, María Adelaida, Saravia, Nancy Gore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031164/
https://www.ncbi.nlm.nih.gov/pubmed/24853871
http://dx.doi.org/10.1371/journal.pntd.0002871
_version_ 1782317493313863680
author Fernández, Olga Lucía
Diaz-Toro, Yira
Ovalle, Clemencia
Valderrama, Liliana
Muvdi, Sandra
Rodríguez, Isabel
Gomez, María Adelaida
Saravia, Nancy Gore
author_facet Fernández, Olga Lucía
Diaz-Toro, Yira
Ovalle, Clemencia
Valderrama, Liliana
Muvdi, Sandra
Rodríguez, Isabel
Gomez, María Adelaida
Saravia, Nancy Gore
author_sort Fernández, Olga Lucía
collection PubMed
description BACKGROUND: Pentavalent antimonials have been the first line treatment for dermal leishmaniasis in Colombia for over 30 years. Miltefosine is administered as second line treatment since 2005. The susceptibility of circulating populations of Leishmania to these drugs is unknown despite clinical evidence supporting the emergence of resistance. METHODOLOGY/PRINCIPAL FINDINGS: In vitro susceptibility was determined for intracellular amastigotes of 245 clinical strains of the most prevalent Leishmania Viannia species in Colombia to miltefosine (HePC) and/or meglumine antimoniate (Sb(V)); 163, (80%) were evaluated for both drugs. Additionally, susceptibility to Sb(V) was examined in two cohorts of 85 L. V. panamensis strains isolated between 1980–1989 and 2000–2009 in the municipality of Tumaco. Susceptibility to each drug differed among strains of the same species and between species. Whereas 68% of L. V. braziliensis strains presented in vitro resistance to HePC, 69% were sensitive to Sb(V). Resistance to HePC and Sb(V) occurred respectively, in 20% y 21% of L. panamensis strains. Only 3% of L. V. guyanensis were resistant to HePC, and none to Sb(V). Drug susceptibility differed between geographic regions and time periods. Subpopulations having disparate susceptibility to Sb(V) were discerned among L. V. panamensis strains isolated during 1980–1990 in Tumaco where resistant strains belonged to zymodeme 2.3, and sensitive strains to zymodeme 2.2. CONCLUSIONS/SIGNIFICANCE: Large scale evaluation of clinical strains of Leishmania Viannia species demonstrated species, population, geographic, and epidemiologic differences in susceptibility to meglumine antimoniate and miltefosine, and provided baseline information for monitoring susceptibility to these drugs. Sensitive and resistant clinical strains within each species, and zymodeme as a proxy marker of antimony susceptibility for L. V. panamensis, will be useful in deciphering factors involved in susceptibility and the distribution of sensitive and resistant populations.
format Online
Article
Text
id pubmed-4031164
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40311642014-05-28 Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia Fernández, Olga Lucía Diaz-Toro, Yira Ovalle, Clemencia Valderrama, Liliana Muvdi, Sandra Rodríguez, Isabel Gomez, María Adelaida Saravia, Nancy Gore PLoS Negl Trop Dis Research Article BACKGROUND: Pentavalent antimonials have been the first line treatment for dermal leishmaniasis in Colombia for over 30 years. Miltefosine is administered as second line treatment since 2005. The susceptibility of circulating populations of Leishmania to these drugs is unknown despite clinical evidence supporting the emergence of resistance. METHODOLOGY/PRINCIPAL FINDINGS: In vitro susceptibility was determined for intracellular amastigotes of 245 clinical strains of the most prevalent Leishmania Viannia species in Colombia to miltefosine (HePC) and/or meglumine antimoniate (Sb(V)); 163, (80%) were evaluated for both drugs. Additionally, susceptibility to Sb(V) was examined in two cohorts of 85 L. V. panamensis strains isolated between 1980–1989 and 2000–2009 in the municipality of Tumaco. Susceptibility to each drug differed among strains of the same species and between species. Whereas 68% of L. V. braziliensis strains presented in vitro resistance to HePC, 69% were sensitive to Sb(V). Resistance to HePC and Sb(V) occurred respectively, in 20% y 21% of L. panamensis strains. Only 3% of L. V. guyanensis were resistant to HePC, and none to Sb(V). Drug susceptibility differed between geographic regions and time periods. Subpopulations having disparate susceptibility to Sb(V) were discerned among L. V. panamensis strains isolated during 1980–1990 in Tumaco where resistant strains belonged to zymodeme 2.3, and sensitive strains to zymodeme 2.2. CONCLUSIONS/SIGNIFICANCE: Large scale evaluation of clinical strains of Leishmania Viannia species demonstrated species, population, geographic, and epidemiologic differences in susceptibility to meglumine antimoniate and miltefosine, and provided baseline information for monitoring susceptibility to these drugs. Sensitive and resistant clinical strains within each species, and zymodeme as a proxy marker of antimony susceptibility for L. V. panamensis, will be useful in deciphering factors involved in susceptibility and the distribution of sensitive and resistant populations. Public Library of Science 2014-05-22 /pmc/articles/PMC4031164/ /pubmed/24853871 http://dx.doi.org/10.1371/journal.pntd.0002871 Text en © 2014 Fernández et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Fernández, Olga Lucía
Diaz-Toro, Yira
Ovalle, Clemencia
Valderrama, Liliana
Muvdi, Sandra
Rodríguez, Isabel
Gomez, María Adelaida
Saravia, Nancy Gore
Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
title Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
title_full Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
title_fullStr Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
title_full_unstemmed Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
title_short Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
title_sort miltefosine and antimonial drug susceptibility of leishmania viannia species and populations in regions of high transmission in colombia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031164/
https://www.ncbi.nlm.nih.gov/pubmed/24853871
http://dx.doi.org/10.1371/journal.pntd.0002871
work_keys_str_mv AT fernandezolgalucia miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia
AT diaztoroyira miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia
AT ovalleclemencia miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia
AT valderramaliliana miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia
AT muvdisandra miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia
AT rodriguezisabel miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia
AT gomezmariaadelaida miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia
AT saravianancygore miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia